Aptevo Therapeutics mipletamig combination enabled 21% of frontline AML patients to advance to stem cell transplant
APVO•Aptevo Therapeutics said a mipletamig combination enabled 21% of frontline AML patients to advance to stem cell transplant. The company expects its RAINIER trial to conclude by year-end, with Phase 2 initiation anticipated in the first half of 2027.
1. Trial update
A SEC filing said a mipletamig combination enabled 21% of frontline AML patients to advance to stem cell transplant. Aptevo Therapeutics said the RAINIER trial is expected to conclude by year-end and Phase 2 initiation is anticipated in the first half of 2027.
